STE

As of 2026-10-26, STE scores 50out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. STE trades at $230.12, within its fair-value band.

STE scores 50 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 50. Its strongest factor is value at 70 (strong), where it screens cheap on the model's valuation inputs, followed by sentiment at 52. The weakest is volume at 43, where volume gives little confirmation. Among Healthcare stocks it ranks in roughly the top 50% of the Healthcare names the model scores.

On valuation, STE is priced around the middle of its recent range. The blended composite before the macro overlay was 51. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on STE, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where STE sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for STE runs $198.00–$257.39. Current price $230.12 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.